The use of intravenous immunoglobulin for rheumatic diseases is explored in the Review, with a focus on the conditions for which its use is best indicated, those for which it shows promise but remains unproven, and the future developments that might help to clarify its potential as a first-line therapy.
- Jagadeesh Bayry
- Vir Singh Negi
- Srini V. Kaveri